Sangamo

This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.

Sangamo’s first gene-editing trial doesn’t convince investors

Sangamo’ s first gene-editing trial doesn’ t convince investors. Market spooked by inconclusive early results. ... Elaprase costs hundreds of thousands of dollars per year, however, and Sangamo is hoping its one-shot therapy could do away with the

Latest news

Spark sputters on haemophilia A gene therapy safety scare

meeting the factor threshold because of reactions – suggesting that could affect SPK-8011’s competitive profile compared to other haemophilia A gene therapies from the likes of BioMarin Pharma, Pfizer/Sangamo
Sangamo bulks up in cell therapy with TxCell acquisition

Sangamo bulks up in cell therapy with TxCell acquisition. Hopes to start cell-based immunotherapy trials next year. ... Sangamo has agreed a 72m deal to take control of French biotech TxCell, eyeing a regulatory T cell (Treg) platform that it says would
Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future

Competition in the therapy area is hotting up, however: Bluebird has recently produced compelling data on its beta-thalassemia gene therapy, with Sangamo also pursuing a similar approach.
Sarepta soars on positive Duchenne data

Sarepta’s experimental treatment one of a clutch of DMD gene therapies in clinical testing along with candidates from Sangamo, Bamboo/Pfizer, and Solid Biosciences.
Freeline raises £88m to accelerate haemophilia gene therapy

Following after is Sangamo with SB-FIX in phase I/II testing. Baxalta (now part of Shire) was an early player in the field with its BAX 335 therapy but has

More from news
Approximately 6 fully matching, plus 10 partially matching documents found.

Latest Intelligence

Deal Watch table for January 2014

320. Sangamo/Biogen Idec . Collaboration and licence. Development of therapies for haemoglobinopathies using zinc finger genome editing.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Eric Rhodes becomes CEO of ERS Genomics

Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Scientific Team Lead: Competitive Salary

Account Director – Global Healthcare PR: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior Account Executive – Medical Communications: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Project / Account Manager (Medical Education): Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Editorial Director – Medical Education: Neg

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Manager, Healthcare Advertising: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Associate Medical Director: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Experienced Editor, London, Medical Communications: Competitive package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director - Digital: Great salary and benefits

Senior Account Director development role to Business Director, H...: Excellent package

Director – Head of Public Affairs: Neg

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Redefining communications excellence: How to be heard in today’s multichannel, multistakeholder, multimedia world...
AstraZeneca: building a new ‘open innovation’ pharma company: The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
In conversation with Pfizer’s Erik Nordkamp: Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...